What Is Boundless Bio, Inc. (BOLD) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Boundless Bio, Inc.'s intrinsic value is estimated at a composite fair value of $2.66. While the stock appears modestly undervalued at $2.47 (implied upside of +7.8%), our analysis suggests a thinner margin of safety across 4 of 7 bullish models. Notably, Dynamic NAV sees the most upside at +82.5% (fair value: $4.51), while Bayesian DCF is the most conservative at -57.8% ($1.04). The spread between these extremes — +140.3% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About BOLD?
7 of 13 models are currently active for BOLD. Of these, 5 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates BOLD's intrinsic value at $1.04, implying -57.8% downside from the current price. See which stocks rank higher →
How Does BOLD Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, BOLD ranks #293 by Quality of Company score. CirclFi's QOC score of 4.4/10 evaluates 32 fundamental signals. A score of 4.4 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Boundless Bio, Inc. competes in an environment where FDA approval probability often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is BOLD a Value Trap?
CirclFi's Value Trap algorithm assigns BOLD a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Boundless Bio, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Boundless Bio, Inc. is rated at 4.4/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +140.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every BOLD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across BOLD's 7 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad